1. Home
  2. MMU vs CGEM Comparison

MMU vs CGEM Comparison

Compare MMU & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Managed Municipals Fund Inc.

MMU

Western Asset Managed Municipals Fund Inc.

HOLD

Current Price

$10.49

Market Cap

567.5M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$10.96

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMU
CGEM
Founded
1992
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
567.5M
671.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MMU
CGEM
Price
$10.49
$10.96
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$28.00
AVG Volume (30 Days)
170.7K
1.1M
Earning Date
01-01-0001
02-26-2026
Dividend Yield
4.92%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.60
$5.68
52 Week High
$10.45
$13.33

Technical Indicators

Market Signals
Indicator
MMU
CGEM
Relative Strength Index (RSI) 56.66 56.55
Support Level $10.37 $9.41
Resistance Level $10.48 $10.70
Average True Range (ATR) 0.10 0.60
MACD 0.01 -0.05
Stochastic Oscillator 79.76 79.64

Price Performance

Historical Comparison
MMU
CGEM

About MMU Western Asset Managed Municipals Fund Inc.

Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: